Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/11/26
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue EstimatesZacks Investment Research • 02/26/26
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial GuidanceGlobeNewsWire • 02/26/26
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026GlobeNewsWire • 02/17/26
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026GlobeNewsWire • 02/05/26
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 01/08/26
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 01/07/26
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewsWire • 01/07/26
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)GlobeNewsWire • 11/04/25
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 10/30/25
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 10/30/25
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux DiseaseGlobeNewsWire • 10/25/25
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific MeetingGlobeNewsWire • 10/23/25
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025GlobeNewsWire • 10/20/25
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business OfficerGlobeNewsWire • 10/06/25
Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?Zacks Investment Research • 09/08/25
Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a BetZacks Investment Research • 08/22/25
Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D FilingGlobeNewsWire • 08/20/25